SCHEMBL17018264

SCHEMBL17018264

CC(C)OC(=O)N1C[C@H](C)N(C(=O)C2CC2)c2ccc(-c3cnn(CCN(C)C)c3)cc21

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 10/20 0.53
▸ IDH1 O75874 3/20 0.37
▸ NEK2 P51955 3/20 0.36
▸ FLT3 P36888 2/20 0.36
▸ TGFBR1 P36897 1/20 0.35
▸ AURKA O14965 1/20 0.34
▸ KHK P50053 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ CREBBP Q92793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16722067 0.92 BRD4 (0.59) BRD4NEK2FLT3TGFBR1AURKA
SCHEMBL16722069 0.92 BRD4 (0.59) BRD4NEK2FLT3TGFBR1AURKA
SCHEMBL17018261 0.91 BRD4 (0.49) BRD4NEK2FLT3TGFBR1NAMPT
SCHEMBL17018109 0.91 BRD4 (0.55) BRD4IDH1NAMPTCREBBP
SCHEMBL17018108 0.89 BRD4 (0.54) BRD4IDH1TGFBR1
SCHEMBL21249915 0.89 BRD4 (0.57) BRD4IDH1TGFBR1
SCHEMBL17018105 0.89 BRD4 (0.53) BRD4IDH1FLT3
SCHEMBL17018253 0.89 BRD4 (0.53) BRD4IDH1NAMPT
SCHEMBL16722151 0.88 BRD4 (0.53) BRD4IDH1NEK2FLT3TGFBR1
SCHEMBL17018103 0.88 BRD4 (0.54) BRD4IDH1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377769-B2 Benzopiperazine compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2019-08-13 — — US disclosed
US-20160256458-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 — — US disclosed
US-20160257699-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 — — US disclosed
US-9422281-B2 Benzopiperazine compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-08-23 — — US disclosed
US-20150232465-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232465-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885IDH1 1674/4885NEK2 933/4885
US-20160256458-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885IDH1 1674/4885NEK2 933/4885
US-10377769-B2 Benzopiperazine compositions as BET bromodomain inhibitors BRD4, BRPF3, BRD7 BRD4 1/4885IDH1 1674/4885NEK2 933/4885
US-20160257699-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885IDH1 1674/4885NEK2 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback